New Research on Carrier Proteins - Iron-Binding Proteins Shows Promise in Treating Colitis

Strategic Insights -

Scientists at Ningbo University in the People's Republic of China have discovered that low-molecular-weight bovine lactoferrin hydrolysates (bLFH-L) can help alleviate symptoms of colitis, a chronic inflammation of the colon. According to a new study published in the journal Food Bioscience, bLFH-L exhibited significant in vitro antioxidant capacity and suppressed NF-kappa B-mediated inflammation. The research team, led by Maolin Tu, also found that bLFH-L beneficially modulated the gut microbiota, decreasing Escherichia-Shigella while enriching Lactobacillus and Bacteroides.

Key Takeaways:

  • The study found that low-molecular-weight bovine lactoferrin hydrolysates (bLFH-L) exhibited significant in vitro antioxidant capacity and suppressed NF-kappa B-mediated inflammation.
  • bLFH-L was shown to be effective in alleviating symptoms of colitis in a murine dextran sulfate sodium (DSS)-induced colitis model, reducing intestinal inflammation and enhancing host antioxidant defenses.
  • The research team found that bLFH-L beneficially modulated the gut microbiota, decreasing Escherichia-Shigella while enriching Lactobacillus and Bacteroides.
  • The study concluded that bLFH-L acts as a multi-target ingredient and exerts protective effects against colitis through synergistic antioxidant, anti-inflammatory, barrier-fortifying mechanisms, and favorable microbiota modulation.
  • The research suggests that bLFH-L has potential as a promising functional food ingredient for the prevention and management of intestinal inflammation.
  • The study highlights the importance of gut microbiota modulation in alleviating symptoms of colitis.
  • The research team found that specific microbial shifts correlated with improved host gene expression related to barrier function, anti-inflammatory responses, and antioxidant defense.

Statistics:

  • 16S rRNA sequencing revealed that bLFH-L beneficially modulated the gut microbiota, decreasing Escherichia-Shigella while enriching Lactobacillus and Bacteroides, and normalizing Akkermansia levels.
  • The study found that oral bLFH-L (300 mg/kg/day) administration markedly attenuated disease severity, reduced intestinal inflammation, and enhanced host antioxidant defenses in a murine DSS-induced colitis model.
  • The research suggested that bLFH-L beneficially modulated the gut microbiota, improving host gene expression related to barrier function, anti-inflammatory responses, and antioxidant defense.

Sources:

  • "Bovine Lactoferrin Peptides From Sequential Enzymatic Hydrolysis Alleviate Colitis Through Synergistic Enhancement of Gut Barrier Integrity and Microbiota Homeostasis" published in Food Bioscience, 2025;73.
  • NewsRx. Investigators from Ningbo University Zero in on Iron-Binding Proteins (Bovine Lactoferrin Peptides From Sequential Enzymatic Hydrolysis Alleviate Colitis Through Synergistic Enhancement of Gut Barrier Integrity and Microbiota Homeostasis). Life Science Weekly. November 4, 2025; p 2074.